A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer.

Conclusions: Shrinking field radiotherapy during chemoradiotherapy in stage III non-small cell lung cancer seems safe with acceptable toxicities and relapse, and potentially spares normal tissues and enables dose escalation. Prospective trials are warranted. PMID: 29552324 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research